Updated:
Esplanade HealthTech Ventures
Esplanade Ventures is Canada's leading digital health VC, investing early in technology companies transforming care across the U.S. and Canada.
Esplanade HealthTech Ventures
Esplanade Ventures is Canada's leading digital health VC, investing early in technology companies transforming care across the U.S. and Canada. The firm is made up of healthcare operators, founders, and investors with over 100 years of collective experience. They invest in early-stage and high-growth companies redefining healthcare delivery, with a focus on digital health and preference for AI software, and support portfolio companies with hands-on guidance, commercial introductions, and GTM strategy.
General information
Firm type
Venture Capital
Year founded
2019
Location
Region
North America
Country
Canada
City
Westmount
Corporate office
Westmount, Montreal, Canada
Principals
Dr. Sheldon Elman
MD — Co-Founder & Chairman
Stuart M. Elman — Co-Founder
Josh Blair — Venture Partner
Ella Seitz — Managing Partner
Alexandre Nossovskoi — Principal
Kavuchaljan Ganesathasan — VP Finance
Simon Kennedy — Senior Advisor
Dr. Yosef Berlyand
MD — Advisor
Sector focus
Frequently asked questions
How does the firm source its health-technology deal flow?
Esplanade derives deal flow from Quebec's dense academic-medical research cluster, including McGill University and the Université de Montréal health networks. This proximity to publicly funded clinical science gives the firm early exposure to spin-out intellectual property before it reaches broader auction-market processes.
Does Esplanade lead investment rounds or co-invest alongside other funds?
The firm is structured to lead or co-lead early-stage rounds and will participate alongside other specialized health-tech or generalist venture funds. Its strategy does not preclude syndication with larger later-stage investors when portfolio companies progress beyond Series A.
Which health-tech subsectors does Esplanade explicitly avoid?
Based on its disclosed focus and typical investment profile, the firm does not appear to pursue biopharmaceutical drug development, large-scale hospital buyouts, or health-service businesses lacking a proprietary technology or device layer. Its activity is centered on digital health platforms, AI diagnostics, and regulated medical devices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: